Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
BackgroundPulmonary hypertension due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is classified as group 3 pulmonary hypertension. Inhaled treprostinil, a prostaglandin I2 analogue also known as prostacyclin, has recently been approved as a first drug for patie...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2023-08-01
|
| Ráidu: | Frontiers in Medicine |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1217156/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
